- Home
- XBIT vs CHRS Comparison
XBIT vs CHRS Comparison
Compare XBIT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- CHRS
- Stock Information
- Founded
- XBIT 2005
- CHRS 2010
- Country
- XBIT United States
- CHRS United States
- Employees
- XBIT N/A
- CHRS N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XBIT Health Care
- CHRS Health Care
- Exchange
- XBIT Nasdaq
- CHRS Nasdaq
- Market Cap
- XBIT 194.5M
- CHRS 191.3M
- IPO Year
- XBIT 2015
- CHRS 2014
- Fundamental
- Price
- XBIT $3.65
- CHRS $1.24
- Analyst Decision
- XBIT
- CHRS Strong Buy
- Analyst Count
- XBIT 0
- CHRS 4
- Target Price
- XBIT N/A
- CHRS $5.38
- AVG Volume (30 Days)
- XBIT 86.8K
- CHRS 2.0M
- Earning Date
- XBIT 03-14-2025
- CHRS 03-12-2025
- Dividend Yield
- XBIT N/A
- CHRS N/A
- EPS Growth
- XBIT N/A
- CHRS N/A
- EPS
- XBIT N/A
- CHRS N/A
- Revenue
- XBIT N/A
- CHRS $304,340,000.00
- Revenue This Year
- XBIT N/A
- CHRS $2.47
- Revenue Next Year
- XBIT N/A
- CHRS N/A
- P/E Ratio
- XBIT N/A
- CHRS N/A
- Revenue Growth
- XBIT N/A
- CHRS 44.19
- 52 Week Low
- XBIT $3.51
- CHRS $0.66
- 52 Week High
- XBIT $9.96
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- XBIT 30.13
- CHRS 37.51
- Support Level
- XBIT $3.60
- CHRS $1.38
- Resistance Level
- XBIT $4.00
- CHRS $1.45
- Average True Range (ATR)
- XBIT 0.26
- CHRS 0.13
- MACD
- XBIT 0.06
- CHRS -0.04
- Stochastic Oscillator
- XBIT 4.67
- CHRS 4.50
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.